Further clinical studies are needed to clarify if restoration of normal activity levels of ADAMTS13 (i.e., with plasma or recombinant ADAMTS13 infusions) may neutralize VWF-system prevalence and prevent microvascular occlusion and organ failure in patients with SIRS and sepsis. This evidence concerns the gene ADAMTS13 and Sepsis.